Good news for newly approved Alzheimer's drug

CMS begins Medicare coverage review for Aduhelm

The CMS announced that it has initiated a National Coverage Determination review process for Biogen's newly approved Alzheimer's disease drug Aduhelm, which could cost $56,000 per year, and it expects to release a proposal within six months and a final determination within nine months. The agency will consider clinical evidence, public comments and guidelines from professional societies when drafting a policy.

Full Story: Reuters (7/12), FierceHealthcare (7/12)